Virtus ETF Advisers LLC Protagonist Therapeutics, Inc Transaction History

Virtus ETF Advisers LLC

$206 Million
Q3 2024

A detailed history of Virtus ETF Advisers LLC transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Virtus ETF Advisers LLC holds 2,680 shares of PTGX stock, worth $109,049. This represents 0.06% of its overall portfolio holdings.

Number of Shares

2,680

Previous 2,635 1.71%

Holding current value

$109,049

Previous $91,000 31.87%

% of portfolio

0.06%

Previous 0.05%

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$33.72 - $47.33 $1,517 - $2,129	45 Added 1.71%	2,680 $120,000
Q2 2024 Aug 14, 2024	SELL	$24.66 - $34.8 $37,976 - $53,591	-1,540 Reduced 36.89%	2,635 $91,000
Q1 2024 May 15, 2024	SELL	$21.79 - $32.15 $6,144 - $9,066	-282 Reduced 6.33%	4,175 $120,000
Q4 2023 Feb 15, 2024	BUY	$14.05 - $23.44 $14,288 - $23,838	1,017 Added 29.56%	4,457 $102,000
Q3 2023 Nov 07, 2023	SELL	$16.68 - $23.66 $5,771 - $8,186	-346 Reduced 9.14%	3,440 $57,000
Q2 2023 Aug 14, 2023	SELL	$18.02 - $29.36 $117,130 - $190,840	-6,500 Reduced 63.19%	3,786 $104,000
Q1 2023 May 15, 2023	SELL	$10.78 - $25.38 $42,570 - $100,225	-3,949 Reduced 27.74%	10,286 $236,000
Q4 2022 Feb 14, 2023	SELL	$7.36 - $11.17 $14 - $22	-2 Reduced 0.01%	14,235 $155,000
Q3 2022 Nov 14, 2022	BUY	$7.86 - $11.71 $848 - $1,264	108 Added 0.76%	14,237 $120,000
Q2 2022 Aug 12, 2022	BUY	$7.06 - $25.52 $62,925 - $227,459	8,913 Added 170.88%	14,129 $112,000
Q1 2022 May 16, 2022	SELL	$23.34 - $36.08 $7,118 - $11,004	-305 Reduced 5.52%	5,216 $124,000
Q4 2021 Feb 14, 2022	BUY	$17.63 - $37.1 $6,188 - $13,022	351 Added 6.79%	5,521 $189,000
Q3 2021 Nov 15, 2021	SELL	$12.95 - $49.69 $3,509 - $13,465	-271 Reduced 4.98%	5,170 $92,000
Q2 2021 Aug 10, 2021	SELL	$25.57 - $44.88 $227,700 - $399,656	-8,905 Reduced 62.07%	5,441 $244,000
Q1 2021 May 17, 2021	BUY	$19.02 - $31.15 $4,640 - $7,600	244 Added 1.73%	14,346 $372,000
Q4 2020 Feb 12, 2021	SELL	$18.49 - $25.13 $91,451 - $124,292	-4,946 Reduced 25.97%	14,102 $284,000
Q3 2020 Nov 13, 2020	SELL	$15.19 - $22.4 $39,357 - $58,038	-2,591 Reduced 11.97%	19,048 $372,000
Q2 2020 Aug 05, 2020	BUY	$6.19 - $18.84 $133,945 - $407,678	21,639 New	21,639 $382,000

Others Institutions Holding PTGX

# of Institutions

247

Shares Held

56.4M

Call Options Held

76.3K

Put Options Held

114K

View Full List

About Protagonist Therapeutics, Inc

Ticker PTGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,084,100
Market Cap $2B
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...

More about PTGX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtus ETF Advisers LLC with notifications on news.

Account

Virtus ETF Advisers LLC Protagonist Therapeutics, Inc Transaction History